Entrada Therapeutics Inc (TRDA)
15.49
-0.25
(-1.59%)
USD |
NASDAQ |
Jun 10, 15:11
Entrada Therapeutics Enterprise Value: 203.95M for June 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 07, 2024 | 203.95M |
| June 06, 2024 | 205.98M |
| June 05, 2024 | 225.56M |
| June 04, 2024 | 189.10M |
| June 03, 2024 | 202.60M |
| May 31, 2024 | 194.84M |
| May 30, 2024 | 200.24M |
| May 29, 2024 | 192.14M |
| May 28, 2024 | 217.46M |
| May 24, 2024 | 183.36M |
| May 23, 2024 | 179.65M |
| May 22, 2024 | 213.07M |
| May 21, 2024 | 202.60M |
| May 20, 2024 | 189.77M |
| May 17, 2024 | 178.63M |
| May 16, 2024 | 177.28M |
| May 15, 2024 | 161.75M |
| May 14, 2024 | 151.63M |
| May 13, 2024 | 146.90M |
| May 10, 2024 | 156.69M |
| May 09, 2024 | 157.37M |
| May 08, 2024 | 146.90M |
| May 07, 2024 | 141.16M |
| May 06, 2024 | 128.33M |
| May 03, 2024 | 116.85M |
| Date | Value |
|---|---|
| May 02, 2024 | 130.36M |
| May 01, 2024 | 119.89M |
| April 30, 2024 | 72.63M |
| April 29, 2024 | 88.17M |
| April 26, 2024 | 91.88M |
| April 25, 2024 | 88.84M |
| April 24, 2024 | 91.20M |
| April 23, 2024 | 106.69M |
| April 22, 2024 | 113.77M |
| April 19, 2024 | 81.77M |
| April 18, 2024 | 73.69M |
| April 17, 2024 | 84.13M |
| April 16, 2024 | 100.97M |
| April 15, 2024 | 105.74M |
| April 12, 2024 | 107.76M |
| April 11, 2024 | 118.18M |
| April 10, 2024 | 93.31M |
| April 09, 2024 | 118.85M |
| April 08, 2024 | 124.56M |
| April 05, 2024 | 136.66M |
| April 04, 2024 | 137.33M |
| April 03, 2024 | 136.66M |
| April 02, 2024 | 139.01M |
| April 01, 2024 | 134.98M |
| March 31, 2024 | 148.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-91.70M
Minimum
May 09 2022
971.53M
Maximum
Nov 17 2021
167.91M
Average
139.62M
Median
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 1.535B |
| Vertex Pharmaceuticals Inc | 114.48B |
| Sarepta Therapeutics Inc | 11.51B |
| PTC Therapeutics Inc | 2.201B |
| GlycoMimetics Inc | -14.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 23.50M |
| Revenue (Quarterly) | 59.12M |
| Total Expenses (Quarterly) | 38.01M |
| EPS Diluted (Quarterly) | 0.68 |
| Profit Margin (Quarterly) | 39.74% |
| Earnings Yield | 4.07% |
| Operating Earnings Yield | 4.50% |
| Normalized Earnings Yield | 4.067 |